LIFE, US0021202025

aTyr Pharma stock: ATYR2810 shows preclinical cancer activity

Published on 11/20/2026 at 22:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
aTyr Pharma stock gains a new development update as ATYR2810 shows anti-tumor activity in osteosarcoma models. The candidate remains preclinical.

Preclinical findings support ATYR2810 development

  • aTyr presented ATYR2810 findings from osteosarcoma models at the CTOS 2026 annual meeting.
  • The antibody reduced tumor growth and lung metastases in mice, with effects continuing after treatment ended.
  • ATYR2810 remains in preclinical development as a potential NRP2-targeting treatment.
LIFE, US0021202025, Illustration mit AI erstellt.

aTyr Pharma presented new preclinical findings for its NRP2-targeting antibody ATYR2810 on Thursday, November 19, 2026, at the Connective Tissue Oncology Society annual meeting in Seoul. In a GlobeNewswire release, the company said the antibody substantially inhibited osteosarcoma growth and spread to the lungs in preclinical studies.

ATYR2810 targets aggressive cancer models

The research covered primary tumors, lung metastases and patient-derived orthotopic models using spatial transcriptomics and in vivo testing. Treatment with ATYR2810 was associated with lower tumor growth and metastasis in mice, with no overt toxicity observed in the reported experiments.

aTyr also said anti-tumor effects continued after treatment stopped. In one mouse study, treatment ended on day 25 and effects on tumor recurrence lasted through day 45. The company linked the findings to NRP2 expression in malignant osteosarcoma cells and macrophages.

Clinical development remains ahead

ATYR2810 is a fully humanized monoclonal antibody designed to block the neuropilin-2 receptor. The candidate remains in preclinical development; aTyr said it has completed GLP toxicology testing in non-human primates and cGMP manufacturing and views the findings as support for future clinical studies.

aTyr Pharma at a glance

  • Company: aTyr Pharma, Inc.
  • Ticker: ATYR
  • Exchange: Nasdaq
  • ISIN: US0021202025

The broader U.S. market is covered in the S&P 500 market reports.

More news and analyses on aTyr Pharma stock

Disclaimer...
en | US0021202025 | LIFE | boerse | 70541169 | bgmi